News

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF DOSING IN PHASE 1 STUDY OF THERAPY FOR SOCIAL DEFICIT IN AUTISM SPECTRUM DISORDER

Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004 SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin … Continued

Michael J. Fox Foundation Announces Grant Funding to MapLight Therapeutics

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces 19 new grant awards totaling more than $16.5 million to projects that serve our mission to find a cure for Parkinson’s and improved treatments for those living with the disease today. MJFF is funding as many projects as possible, collaborating with the Parkinson’s research community … Continued